335
Participants
Start Date
September 5, 2023
Primary Completion Date
June 25, 2029
Study Completion Date
June 25, 2029
Amlitelimab
Injection Solution: by subcutaneous injection (SCI)
Placebo
Injection Solution: by subcutaneous injection (SCI)
Investigational Site Number : 7100004, Middelburg
Investigational Site Number : 0320009, Buenos Aires
Investigational Site Number : 7100007, Benoni
Investigational Site Number : 0320006, Rosario
Investigational Site Number : 3480011, Gödöllö
Investigational Site Number : 3480012, Százhalombatta
Investigational Site Number : 3480009, Edelény
Investigational Site Number : 3480006, Püspökladány
Investigational Site Number : 7100002, Cape Town
Investigational Site Number : 7100001, Cape Town
Johns Hopkins University School of Medicine- Site Number : 8400012, Baltimore
Investigational Site Number : 4840002, Chihuahua City
Pines Care Research Center LLC- Site Number : 8400028, Pembroke Pines
Investigational Site Number : 7920002, Mersin
Savin Medical Group - Miami- Site Number : 8400015, Miami
Helix Biomedics, LLC - Site Number : 8400029, Boynton Beach
Investigational Site Number : 7920001, Istanbul
Investigational Site Number : 7920003, Izmir
Investigational Site Number : 3800001, Verona
Investigational Site Number : 7920008, Kayseri
Investigational Site Number : 7920005, Kocaeli
Investigational Site Number : 4100004, Daegu
Investigational Site Number : 4840001, Guadalajara
Investigational Site Number : 4840005, Guadalajara
OK Clinical Research, LLC- Site Number : 8400001, Edmond
TTS Research- Site Number : 8400011, Boerne
Investigational Site Number : 3800004, Naples
Treasure Valley Medical Research- Site Number : 8400031, Boise
Bensch Clinical Research LLC- Site Number : 8400004, Stockton
Investigational Site Number : 4840008, Mérida
Investigational Site Number : 1520005, Quillota
Investigational Site Number : 1520006, Talca
Investigational Site Number : 1520001, Santiago
Investigational Site Number : 1520003, Santiago
Investigational Site Number : 1520008, Santiago
Investigational Site Number : 0320002, CABA
Investigational Site Number : 0320008, La Plata
Investigational Site Number : 0320007, Rosario
Investigational Site Number : 0320005, Rosario
Investigational Site Number : 0320004, Ciudad Autonoma Bs As
Investigational Site Number : 0320003, Ciudad Autonoma Buenos Aires
Investigational Site Number : 0320001, Ciudad Autonoma Buenos Aires
Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760002, Vitória
Proar- Site Number : 0760004, Salvador
Instituto Méderi de Pesquisa e Saúde- Site Number : 0760001, Passo Fundo
Irmandade da Santa Casa de Misericordia de Porto Alegre- Site Number : 0760007, Porto Alegre
Hospital Sao Lucas da PUCRS- Site Number : 0760006, Porto Alegre
Hospital das Clinicas de Sao Paulo- Site Number : 0760008, São Paulo
Clínica de Alergia Martti Antila- Site Number : 0760003, Sorocaba
Investigational Site Number : 1240008, Ottawa
Investigational Site Number : 1240007, Trois-Rivières
Investigational Site Number : 3800003, Rome
Investigational Site Number : 3920010, Sakai
Investigational Site Number : 3920005, Chuo-ku
Investigational Site Number : 3920004, Chuo-ku
Investigational Site Number : 3920001, Shinagawa-ku
Investigational Site Number : 3920019, Hiroshima
Investigational Site Number : 6160001, Poznan
Investigational Site Number : 6160006, Krakow
Investigational Site Number : 6160004, Bialystok
Investigational Site Number : 6160003, Elblag
Investigational Site Number : 6160002, Gdansk
Investigational Site Number : 6160007, Tarnów
Investigational Site Number : 4100006, Moncton
Investigational Site Number : 4100001, Seoul
Investigational Site Number : 4100005, Seoul
Investigational Site Number : 4100002, Seoul
Investigational Site Number : 8260001, Bradford
Lead Sponsor
Sanofi
INDUSTRY